MCAL Therapeutics

Treatments of ophthalmic diseases

Operator of a biotechnology company intended to treat ophthalmic diseases. The company advances ophthalmology discoveries from a dry eye platform, enabling healthcare providers to cure their patients.
Domain

Topical Ophthamology

First Partnered

Seed

Current Status

Active

Investors

Tom Mather

Leadership

Thomas Gadek Ph.D, CEO

HQ

Park City, UT

In the News